insights_auto
Why is ALNOV down 3.30%?
Dive Deeperchevron_right
ALNOV:EPA
Novacyt SA
€0.43
arrow_downward
-3.30%(-0.014) 1D
Nov 20, 5:35:10 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNOV...
Open
€0.43
High
€0.44
Low
€0.42
Mkt. cap
28.77M
Avg. vol.
128.00K
Volume
64.11K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.37
Shares outstanding
72.59M
No. of employees
228
Open
€0.43
High
€0.44
Low
€0.42
Mkt. cap
28.77M
Avg. vol.
128.00K
Volume
64.11K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.37
Shares outstanding
72.59M
No. of employees
228
News stories
From web sources and news partners
Traders Union
·
1 hour ago
VIX fear index hits highest level since April 2025 as S&P 500 plunges
Nacionale
·
5 hours ago
Is the stock market down for the year? Only the Nasdaq; the S&P 500 and Dow are barely up for 2026
FXStreet
·
11 hours ago
Dow Jones Industrial Average drops for a fifth day as AI rout widens
Big News Network.com
·
1 hour ago
S&P 500 earnings growth projected to slow to 11% in 2027 as AI investment impulse peaks: Goldman Sachs
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees228
FoundedJul 3, 2006
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitenovacyt.com